CEO of Rare Disease Treatment Company Continues to Cash Out on Stock Options Worth Hundreds of Millions

United Therapeutics Corp (NASDAQ: UTHR) CFO and CEO consecutively exercised stock options and sold the same number of common shares on the open market in late April and mid-May.

On April 30, CFO James Edgemond exercised 10,000 options and sold the resulting shares, generating approximately $5.7 million (about ₩8 billion) in proceeds; he still holds nearly 20,000 shares. On May 7 and 11, CEO Martine A. Rothblatt, under a pre-established Rule 10b5-1 trading plan, disposed of shares worth roughly $5.5–5.7 million on each date, realizing total option gains of about $11 million (around ₩15 billion); her direct and indirect holdings remain substantial.

In its first-quarter 2026 results announced May 6, the company reported a slight year-over-year revenue decline but emphasized growth momentum after positive outcomes in the ADVANCE OUTCOMES and TETON-1 clinical trials for its Tyvaso franchise, a candidate for pulmonary arterial hypertension and pulmonary fibrosis.

On May 13, United Therapeutics partnered with space-pharma startup Varda Space Industries to launch a microgravity-enabled formulation development project for rare pulmonary diseases, accelerating its new-drug portfolio expansion and technological differentiation.

Headquartered in Silver Spring, Maryland, and Research Triangle Park, North Carolina, United Therapeutics is a biotech company specializing in rare cardiopulmonary disorders. Its product portfolio includes Tyvaso and Remodulin for pulmonary arterial hypertension and Unituxin for pediatric neuroblastoma.

Founder and CEO Martine A. Rothblatt established the company in her search for a pulmonary arterial hypertension therapy to save her daughter’s life. United Therapeutics operates as a public-benefit corporation and is developing artificial organs and lung-manufacturing technologies for transplant.